Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PARG | Q86W56 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 9/20 | 0.38 |
| ▸ | FEN1 | P39748 | 9/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19531675 | 0.85 | BRD4 (0.47) | BRD4NSD2MAPTSMN1; SMN2KDM4E | |
| SCHEMBL17680837 | 0.85 | BRD4 (0.47) | BRD4NSD2MAPTSMN1; SMN2KDM4E | |
| SCHEMBL10786818 | 0.83 | BRD4 (0.36) | BRD4NSD2MAPTSMN1; SMN2KDM4E | |
| SCHEMBL2801005 | 0.82 | NSD2 (0.47) | BRD4NSD2MAPTSMN1; SMN2KDM4E | |
| SCHEMBL19538860 | 0.82 | BRD4 (0.46) | BRD4NSD2MAPTSMN1; SMN2KDM4E | |
| SCHEMBL19538961 | 0.82 | BRD4 (0.46) | BRD4NSD2MAPTSMN1; SMN2KDM4E | |
| SCHEMBL20746862 | 0.82 | BRD4 (0.46) | BRD4NSD2MAPTSMN1; SMN2KDM4E | |
| SCHEMBL2803354 | 0.79 | NSD2 (0.58) | NSD2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL17680988 | 0.76 | BRD4 (0.43) | BRD4MEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL13232916 | 0.74 | NSD2 (0.41) | BRD4NSD2MAPTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204360-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| WO-2016055028-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, CREBBP, HDAC1 | BRD4 18/4885NSD2 420/4885MAPT 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.